{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Veru Inc."},"Symbol":{"label":"Symbol","value":"VERU"},"Address":{"label":"Address","value":"48 NW 25TH STREET,SUITE 102 SUITE 1000, MIAMI, Florida, 33137, United States"},"Phone":{"label":"Phone","value":"+1 305 509-6897"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Veru Inc is a biopharmaceutical company focused on urology and oncology. It develops prescription products for benign prostatic hyperplasia hot flashes associated with cancer treatment, male infertility, and novel chemotherapies for a variety of cancers. The company currently operates in two reporting segments: Sexual health business and Research & development. Some of its products include Zuclomiphene, Veru-111, Veru-100, FC2, and Roman Swipes. The company generates the majority of its revenue from the United States."},"CompanyUrl":{"label":"Company Url","value":"https://www.verupharma.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Domingo Rodriguez","title":"Executive VP-Global Clinical Operations"},{"name":"K. Gary Barnette","title":"Chief Scientific Officer"},{"name":"Mitchell Shuster Steiner","title":"Chairman, President & Chief Executive Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}